Rechercher
image du produit
Lancet Oncology, The

S'abonner

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial - 02/11/18

Doi : 10.1016/S1470-2045(18)30528-X 
Mack Roach, ProfMD a, ⁎ , Jennifer Moughan, MS b, Colleen A F Lawton, ProfMD c, Adam P Dicker, ProfMD d, Kenneth L Zeitzer, MD e, Elizabeth M Gore, ProfMD c, Young Kwok, MD f, Michael J Seider, MD g, I-Chow Hsu, ProfMD a, Alan C Hartford, MD h, Eric M Horwitz, ProfMD i, Kosj Yamoah, MD j, Christopher U Jones, MD k, Jeff M Michalski, ProfMD l, W Robert Lee, ProfMD m, Thomas M Pisansky, ProfMD n, Rachel Rabinovitch, ProfMD o, Marvin Rotman, ProfMD p, Rodger M Pryzant, MD q, Harold E Kim, MD r, Charles R Thomas, ProfMD s, William U Shipley, ProfMD t, Howard M Sandler, ProfMD u
a Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA 
b NRG Oncology Statistics and Data Management Center, American College of Radiology, Pittsburgh, PA, USA 
c Medical College Wisconsin, Milwaukee, WI, USA 
d Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA 
e Albert Einstein Medical Center, Philadelphia, PA, USA 
f University of Maryland Medical System, Baltimore, MD, USA 
g Akron City Hospital, Akron, PA, USA 
h Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA 
i Fox Chase Cancer Center, Philadelphia, PA, USA 
j H Lee Moffitt Cancer Center, Tampa, FL, USA 
k Sutter Cancer Research Consortium, Sacramento, CA, USA 
l Washington University, St Louis, MO, USA 
m Wake Forest University, Winston Salem, NC, USA 
n Mayo Clinic, Rochester, MN, USA 
o University of Colorado, Denver, CO, USA 
p SUNY Brooklyn, Brooklyn, NY, USA 
q Maine Medical Center, Portland, ME, USA 
r Wayne State University, Detroit, MI, USA 
s Oregon Health and Science University, Portland, OR, USA 
t Massachusetts General Hospital, Boston, MA, USA 
u Cedars-Sinai Medical Center, Los Angeles, CA, USA 

* Correspondence to: Prof Mack Roach, 3rd, Department of Radiation Oncology, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143–1708, USA Department of Radiation Oncology University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco CA 94143–1708 USA

Summary

Background

The NRG/RTOG 9413 study showed that whole pelvic radiotherapy (WPRT) plus neoadjuvant hormonal therapy (NHT) improved progression-free survival in patients with intermediate-risk or high-risk localised prostate cancer compared with prostate only radiotherapy (PORT) plus NHT, WPRT plus adjuvant hormonal therapy (AHT), and PORT plus AHT. We provide a long-term update after 10 years of follow-up of the primary endpoint (progression-free survival) and report on the late toxicities of treatment.

Methods

The trial was designed as a 2 × 2 factorial study with hormonal sequencing as one stratification factor and radiation field as the other factor and tested whether NHT improved progression-free survival versus AHT, and NHT plus WPRT versus NHT plus PORT. Eligible patients had histologically confirmed, clinically localised adenocarcinoma of the prostate, an estimated risk of lymph node involvement of more than 15% and a Karnofsky performance status of more than 70, with no age limitations. Patients were randomly assigned (1:1:1:1) by permuted block randomisation to receive either NHT 2 months before and during WPRT followed by a prostate boost to 70 Gy (NHT plus WPRT group), NHT 2 months before and during PORT to 70 Gy (NHT plus PORT group), WPRT followed by 4 months of AHT (WPRT plus AHT group), or PORT followed by 4 months of AHT (PORT plus AHT group). Hormonal therapy was combined androgen suppression, consisting of goserelin acetate 3·6 mg once a month subcutaneously or leuprolide acetate 7·5 mg once a month intramuscularly, and flutamide 250 mg twice a day orally for 4 months. Randomisation was stratified by T stage, Gleason Score, and prostate-specific antigen concentration. NHT was given 2 months before radiotherapy and was continued until radiotherapy completion; AHT was given at the completion of radiotherapy for 4 months. The primary endpoint progression-free survival was analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00769548. The trial has been terminated to additional follow-up collection and this is the final analysis for this trial.

Findings

Between April 1, 1995, and June 1, 1999, 1322 patients were enrolled from 53 centres and randomly assigned to the four treatment groups. With a median follow-up of 8·8 years (IQR 5·07–13·84) for all patients and 14·8 years (7·18–17·4) for living patients (n=346), progression-free survival across all timepoints continued to differ significantly across the four treatment groups (p=0·002). The 10-year estimates of progression-free survival were 28·4% (95% CI 23·3–33·6) in the NHT plus WPRT group, 23·5% (18·7–28·3) in the NHT plus PORT group, 19·4% (14·9–24·0) in the WPRT plus AHT group, and 30·2% (25·0–35·4) in the PORT plus AHT group. Bladder toxicity was the most common grade 3 or worse late toxicity, affecting 18 (6%) of 316 patients in the NHT plus WPRT group, 17 (5%) of 313 in the NHT plus PORT group, 22 (7%) of 317 in the WPRT plus AHT group, and 14 (4%) of 315 in the PORT plus AHT group. Late grade 3 or worse gastrointestinal adverse events occurred in 22 (7%) of 316 patients in the NHT plus WPRT group, five (2%) of 313 in the NHT plus PORT group, ten (3%) of 317 in the WPRT plus AHT group, and seven (2%) of 315 in the PORT plus AHT group.

Interpretation

In this cohort of patients with intermediate-risk and high-risk localised prostate cancer, NHT plus WPRT improved progression-free survival compared with NHT plus PORT and WPRT plus AHT at long-term follow-up albeit increased risk of grade 3 or worse intestinal toxicity. Interactions between radiotherapy and hormonal therapy suggests that WPRT should be avoided without NHT.

Funding

National Cancer Institute.

Le texte complet de cet article est disponible en PDF.

Plan


© 2018  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 19 - N° 11

P. 1504-1515 - novembre 2018 Retour au numéro
Article précédent Article précédent
  • One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study
  • Sophia Zackrisson, Kristina Lång, Aldana Rosso, Kristin Johnson, Magnus Dustler, Daniel Förnvik, Hannie Förnvik, Hanna Sartor, Pontus Timberg, Anders Tingberg, Ingvar Andersson
| Article suivant Article suivant
  • Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial
  • Galina Velikova, Linda Jane Williams, Sarah Willis, J Michael Dixon, Juliette Loncaster, Matthew Hatton, Jacqueline Clarke, Ian H Kunkler, Nicola S Russell, MRC SUPREMO trial UK investigators, A Alhasso, D Adamson, H Algurafi, R Allerton, C Anandadas, A Bahl, L Barraclough, P Barrett-Lee, U Barthakur, C Bedi, M Beresford, J Bishop, G Blackman, P Bliss, D Bloomfield, M Blunt, T Branson, L Brazil, A Brunt, A Chakrabarti, A Chittalie, M Churn, J Clarke, S Cleator, P Crellin, F Danwata, S De-Silva-Minor, A Dhadda, A Eicholz, I Fernando, J Forrest, J Fraser, K Geropantas, A Goodman, R Grieve, M Griffin, M Hadaki, A Hall, M Hatton, J Hicks, S Hignett, M Hogg, R Jyothirmayi, M Khan, S Kumar, P Lawton, D Lee, C Lewinski, C Lim, I Locke, J Loncaster, G Lumsden, S Lupton, B Magee, J Marshall, S Masinghe, C McGregor, M McLennan, P Memtsa, D Milanovic, V Misra, N Mithal, MB Mukesh, A Neal, S Needleman, M Persic, M Quigley, S Raj, P Riddle, D Ritchie, F Roberts, P Robson, H Roe, M Rolles, N Shah, R Sharma, E Sherwin, P Simmonds, G Skailles, S Skaria, W Soe, R Sripadam, A Stevens, A Stockdale, N Storey, N Storey, I Syndikus, N Thorp, N Thorp, S Upadhyay, M Varughese, N Walji, R Welch, T Wells, V Wolstenholme, V Wolstenholme, P Woodings, F Yuille

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.